Biocartis Group NV
ISIN: BE0974281132 | Ticker: BCART | LEI: 549300J4HOJL5KG8HY54
Country: Belgium
Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis.
Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.
2007
Served areaWorldwide
Headcount500
HeadquartersGeneraal De Wittelaan 11B, 2800 Mechelen, Antwerpen – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 210,517,000.00 | 142,480,000.00 | 114,277,000.00 |
| Noncurrent Assets | N/A | 50,534,000.00 | 47,354,000.00 | 44,343,000.00 |
| Property Plant And Equipment | N/A | 40,098,000.00 | 37,192,000.00 | 31,527,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 5,645,000.00 | 5,067,000.00 | 4,770,000.00 |
| Investments In Joint Ventures | N/A | 2,893,000.00 | 2,344,000.00 | 2,538,000.00 |
| Other Noncurrent Receivables | N/A | 426,000.00 | 16,000.00 | N/A |
| Deferred Tax Assets | N/A | 1,472,000.00 | 1,595,000.00 | 1,664,000.00 |
| Other Noncurrent Financial Assets | N/A | 0.00 | 1,140,000.00 | N/A |
| Other Noncurrent Assets | N/A | N/A | 16,000.00 | 204,000.00 |
| Current Assets | N/A | 159,983,000.00 | 95,126,000.00 | 69,934,000.00 |
| Inventories | N/A | 15,712,000.00 | 16,106,000.00 | 18,905,000.00 |
| Current Trade Receivables | N/A | N/A | 16,206,000.00 | 16,697,000.00 |
| Other Current Receivables | N/A | N/A | 6,556,000.00 | 2,236,000.00 |
| Cash and cash equivalents | 178,725,000.00 | 123,668,000.00 | 53,522,000.00 | 26,125,000.00 |
| Other Current Assets | N/A | 3,155,000.00 | 2,736,000.00 | 5,971,000.00 |
| Equity And Liabilities | N/A | 210,517,000.00 | 142,480,000.00 | 114,277,000.00 |
| Equity | 84,480,000.00 | 36,824,000.00 | -33,897,000.00 | -30,284,000.00 |
| Issued Capital | N/A | -220,657,000.00 | -220,657,000.00 | -220,302,000.00 |
| Retained Earnings | N/A | -455,343,000.00 | -526,405,000.00 | -443,363,000.00 |
| Share Premium | N/A | 711,874,000.00 | 711,874,000.00 | 631,722,000.00 |
| Reserve Of Sharebased Payments | N/A | 6,102,000.00 | 6,862,000.00 | 7,502,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | -33,897,000.00 | -30,284,000.00 |
| Noncurrent Liabilities | N/A | 144,248,000.00 | 142,672,000.00 | 102,112,000.00 |
| Noncurrent Provisions | N/A | N/A | 75,000.00 | 204,000.00 |
| Noncurrent Deferred Income Including Noncurrent Contract Liabilities | N/A | N/A | 313,000.00 | 149,000.00 |
| Current Liabilities | N/A | 29,445,000.00 | 33,705,000.00 | 42,449,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | N/A | 11,560,000.00 | 11,747,000.00 |
| Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 1,822,000.00 | 1,195,000.00 |
| Other Current Liabilities | N/A | 7,587,000.00 | 8,445,000.00 | 8,910,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 43,128,000.00 | 48,269,000.00 | 57,481,000.00 |
| Revenue From Sale Of Goods | 31,893,000.00 | 40,486,000.00 | 45,036,000.00 |
| Revenue From Rendering Of Services | 1,246,000.00 | 1,730,000.00 | 1,377,000.00 |
| Other Income | 12,431,000.00 | 6,629,000.00 | 495,000.00 |
| Other Expense By Nature | 0.00 | 3,244,000.00 | N/A |
| Profit Loss From Operating Activities | -46,862,000.00 | -62,645,000.00 | -47,047,000.00 |
| Finance Costs | 14,569,000.00 | 9,488,000.00 | 21,179,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -532,000.00 | -659,000.00 | N/A |
| Profit Loss Before Tax | -63,162,000.00 | -71,715,000.00 | -65,621,000.00 |
| Income Tax Expense Continuing Operations | -228,000.00 | -243,000.00 | -240,000.00 |
| Profit (loss) | -62,934,000.00 | -71,472,000.00 | -65,381,000.00 |
| Profit Loss Attributable To Owners Of Parent | -62,934,000.00 | -71,472,000.00 | -65,381,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -62,934,000.00 | -71,472,000.00 | -65,381,000.00 |
| Adjustments For Income Tax Expense | N/A | 228,000.00 | -243,000.00 | -240,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 4,042,000.00 | -2,737,000.00 | -5,297,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | -9,748,000.00 | 9,845,000.00 | 10,481,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | -1,698,000.00 | 1,362,000.00 | 1,178,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 1,030,000.00 | 1,134,000.00 | N/A |
| Adjustments For Sharebased Payments | N/A | -1,432,000.00 | 760,000.00 | 640,000.00 |
| Other Adjustments For Noncash Items | N/A | 80,000.00 | 162,000.00 | N/A |
| Other Adjustments To Reconcile Profit Loss | N/A | N/A | -162,000.00 | -78,000.00 |
| Cash Flows From Used In Operations | N/A | N/A | -59,285,000.00 | -38,826,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 7,172,000.00 | 6,429,000.00 | 6,027,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | -3,000.00 | -2,000.00 | N/A |
| Cash Flows From Used In Operating Activities | N/A | -39,267,000.00 | -65,716,000.00 | -44,855,000.00 |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | N/A | 1,000,000.00 | 0.00 | 1,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 3,005,000.00 | 3,686,000.00 | 1,569,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 15,000.00 | 69,000.00 | 368,000.00 |
| Interest Received Classified As Investing Activities | N/A | 13,000.00 | 7,000.00 | 6,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -4,007,000.00 | -3,748,000.00 | -5,431,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 6,000,000.00 | 15,000,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 7,167,000.00 | 7,089,000.00 | 26,301,000.00 |
| Interest Paid Classified As Financing Activities | N/A | N/A | 115,000.00 | 73,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | -50,000.00 | -115,000.00 | N/A |
| Cash Flows From Used In Financing Activities | N/A | -11,523,000.00 | -1,204,000.00 | 22,463,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -54,797,000.00 | -70,668,000.00 | -27,823,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -260,000.00 | 522,000.00 | 426,000.00 |
| Cash and cash equivalents | 178,725,000.00 | 123,668,000.00 | 53,522,000.00 | 26,125,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 29.04.21 | Devogelaere Benoit | Executive member | Buy | EUR 0.00 |
| 28.04.21 | Marcofin BV | Executive member | Buy | EUR 0.00 |
| 27.04.21 | Herman Verrelst | Board | Buy | EUR 0.00 |
| 13.11.20 | Devogelaere Benoit | Executive member | Buy | EUR 0.00 |
| 06.05.20 | Herman Verrelst | Board | Buy | EUR 249,625.00 |
| 06.05.20 | Herman Verrelst | Board | Buy | EUR 0.00 |
| 04.05.20 | Herman Verrelst | Board | Buy | EUR 231,656.00 |
| 04.05.20 | Herman Verrelst | Board | Buy | EUR 15,315.00 |
| 18.12.19 | Devogelaere Benoit | Executive member | Buy | EUR 0.00 |
| 16.12.19 | Welten Ewoud | Executive member | Buy | EUR 0.00 |
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Citadel Europe LLP | 1.00% | 18.12.20 |
| Whitebox Advisors LLC | 1.21% | 16.06.23 |
| Total | 2.21% |
BE0974281132
LEI549300J4HOJL5KG8HY54
SectorHealth Care Equipment & Services
IndustryHealth Care Providers & Services
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.